NL8303549A - Injectieoplossing en werkwijze voor het bereiden daarvan. - Google Patents

Injectieoplossing en werkwijze voor het bereiden daarvan. Download PDF

Info

Publication number: NL8303549A
Authority: NL; Netherlands
Prior art keywords: injection solution; solution; preparing; vitamin; same
Prior art date: 1982-10-27

Application number

NL8303549A

Other languages

English (en)

Dutch (nl)

Original Assignee

Gerot Pharmazeutika

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-10-27

Filing date

1983-10-14

Publication date

1984-05-16

1983-10-14 Application filed by Gerot Pharmazeutika filed Critical Gerot Pharmazeutika

1984-05-16 Publication of NL8303549A publication Critical patent/NL8303549A/nl

Links

239000000243 solution Substances 0.000 title claims description 24
238000002347 injection Methods 0.000 title claims description 11
239000007924 injection Substances 0.000 title claims description 11
238000000034 method Methods 0.000 title claims description 6
FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 12
230000003356 anti-rheumatic effect Effects 0.000 claims description 11
239000003435 antirheumatic agent Substances 0.000 claims description 11
239000013543 active substance Substances 0.000 claims description 10
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 6
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
230000003381 solubilizing effect Effects 0.000 claims description 4
239000003589 local anesthetic agent Substances 0.000 claims description 3
238000007918 intramuscular administration Methods 0.000 claims 2
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
LGYTZKPVOAIUKX-UHFFFAOYSA-N kebuzone Chemical compound O=C1C(CCC(=O)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 LGYTZKPVOAIUKX-UHFFFAOYSA-N 0.000 description 5
229960000194 kebuzone Drugs 0.000 description 5
239000000203 mixture Substances 0.000 description 5
235000011121 sodium hydroxide Nutrition 0.000 description 5
229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 4
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 4
229960002104 cyanocobalamin Drugs 0.000 description 4
235000000639 cyanocobalamin Nutrition 0.000 description 4
239000011666 cyanocobalamin Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
229960003957 dexamethasone Drugs 0.000 description 3
229960004194 lidocaine Drugs 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
125000003346 cobalamin group Chemical group 0.000 description 2
230000006378 damage Effects 0.000 description 2
229960002442 glucosamine Drugs 0.000 description 2
-1 halogenated salicyl anilides Chemical class 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
RLISWLLILOTWGG-UHFFFAOYSA-N salamidacetic acid Chemical compound NC(=O)C1=CC=CC=C1OCC(O)=O RLISWLLILOTWGG-UHFFFAOYSA-N 0.000 description 2
229950000417 salamidacetic acid Drugs 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
239000002904 solvent Substances 0.000 description 2
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000012670 alkaline solution Substances 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
229940051881 anilide analgesics and antipyretics Drugs 0.000 description 1
229940051868 antimigraine drug corticosteroid derivative Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
229940010007 cobalamins Drugs 0.000 description 1
150000001867 cobalamins Chemical class 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
150000002301 glucosamine derivatives Chemical class 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
244000000053 intestinal parasite Species 0.000 description 1
208000018937 joint inflammation Diseases 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
230000037380 skin damage Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
235000019195 vitamin supplement Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NL8303549A 1982-10-27 1983-10-14 Injectieoplossing en werkwijze voor het bereiden daarvan. NL8303549A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AT392982		1982-10-27
AT392982A AT376879B (de)	1982-10-27	1982-10-27	Verfahren zur herstellung einer injektionsloesung

Publications (1)

Publication Number	Publication Date
NL8303549A true NL8303549A (nl)	1984-05-16

Family

ID=3557346

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8303549A NL8303549A (nl)	1982-10-27	1983-10-14	Injectieoplossing en werkwijze voor het bereiden daarvan.

Country Status (7)

Country	Link
AT (1)	AT376879B (fr)
BE (1)	BE898082A (fr)
CH (1)	CH657525A5 (fr)
DE (1)	DE3337304A1 (fr)
FR (1)	FR2535205B1 (fr)
LU (1)	LU85040A1 (fr)
NL (1)	NL8303549A (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3437232A1 (de) *	1984-10-10	1986-04-17	Mack Chem Pharm	Stabilisierte injektionsloesungen von piroxicam
US5962536A (en) *	1998-07-31	1999-10-05	Komer; Gene	Injectable propofol formulations
DE102007012644A1 (de)	2007-03-16	2008-09-18	Bayer Healthcare Ag	Stabilisierung von Vitamin B12
ES2686299T3 (es) *	2010-10-29	2018-10-17	Troikaa Pharmaceuticals Ltd	Composiciones nasales de vitamina B12

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1053736B (de) *	1956-03-02	1959-03-26	Konink Nl Gist & Spiritusfabri	Verfahren zur Erhoehung der Loeslichkeit therapeutisch wirksamer Stoffe in Wasser
DE1249453B (fr) *	1963-10-14
GB1076670A (en) *	1964-11-02	1967-07-19	Chugai Pharmaceutical Co Ltd	A stabilised aqueous hydroxo cobalamin solution
DE2103387C3 (de) *	1971-01-26	1982-05-06	Johann G.W. Opfermann & Sohn, 5070 Bergisch-Gladbach	Verwendung des Hydrochlorids von Glukosamin zur Herstellung von pharmazeutischen Präparaten
AU485607B2 (en) *	1972-12-04	1975-04-24	Ici Australia Limited	Compositions
DE2522187C2 (de) *	1975-05-17	1977-10-28	Byk Gulden Lomberg Chem Fab	Verwendung von Cystein oder dessen Säureadditionssalz und Natriumdisulfit zur Stabilisierung von injizierbaren, einen pH-Wert zwischen 7 und 9 aufweisenden, Vitamin B tief 12 und nichtsteroidal Entzündungshemmer enthaltenden Arzneimitteln
JPS54151668A (en) *	1978-05-22	1979-11-29	Teijin Ltd	Production of fluffed fabric
LU80432A1 (de) *	1978-10-26	1979-03-19	Hoffmann K	Verfahren zum herstellen einer injektionsloesung,die mono-phenylbutazon enthaelt,und injektionsloesung,hergestellt nach diesem verfahren
JPS5675438A (en) *	1979-11-22	1981-06-22	Senjiyu Seiyaku Kk	Method for stabilizing aqueous solution of cyanocobalamin
JPS5675436A (en) *	1979-11-22	1981-06-22	Eisai Co Ltd	Solid pharmaceutical containing cobamamide or mecobalamin
NZ195881A (en) *	1980-12-19	1984-08-24	W Lysaght	Pharmaceutical compositions containing cobalt compounds

1982
- 1982-10-27 AT AT392982A patent/AT376879B/de not_active IP Right Cessation
1983
- 1983-10-07 LU LU85040A patent/LU85040A1/xx unknown
- 1983-10-13 DE DE19833337304 patent/DE3337304A1/de not_active Withdrawn
- 1983-10-14 NL NL8303549A patent/NL8303549A/nl not_active Application Discontinuation
- 1983-10-21 FR FR8316819A patent/FR2535205B1/fr not_active Expired
- 1983-10-26 CH CH580983A patent/CH657525A5/de not_active IP Right Cessation
- 1983-10-26 BE BE0/211771A patent/BE898082A/fr not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE3337304A1 (de)	1984-05-03
LU85040A1 (fr)	1984-03-22
AT376879B (de)	1985-01-10
ATA392982A (de)	1984-06-15
FR2535205B1 (fr)	1987-02-06
BE898082A (fr)	1984-02-15
CH657525A5 (de)	1986-09-15
FR2535205A1 (fr)	1984-05-04

Legal Events

Date	Code	Title	Description
1985-01-01	A85	Still pending on 85-01-01
1990-12-03	BV	The patent application has lapsed

Publication	Publication Date	Title
AU567433B2 (en)	1987-11-19	Specific drug delivery
ES2569949T3 (es)	2016-05-13	Formulaciones farmacéuticas que comprenden un péptido complejado con una dicetopiperazina
EP1349586A4 (fr)	2004-06-30	Systeme d'administration i.v. en ligne de medicaments, a dilution regulable
US9289408B2 (en)	2016-03-22	High concentration baclofen preparations
US4942167A (en)	1990-07-17	Pharmaceutical compositions of piroxicam in aqueous solutions and process for their preparation
CZ104898A3 (cs)	1998-09-16	Nové tekuté stálé formulace na bázi paracetamolu a jejich příprava
JPH06199662A (ja)	1994-07-19	ジクロフェナック塩用非経腸溶液
GB2100985A (en)	1983-01-12	Compositions containing buprenorphine
Laine et al.	1995	Polyethylene glycol nephrotoxicity secondary to prolonged high-dose intravenous lorazepam
US8541459B2 (en)	2013-09-24	Pharmaceutical composition
KR101202649B1 (ko)	2012-11-19	소듐 디클로페낙 및 β-시클로덱스트린을 포함하는 주사용약학 조성물
CA2270004C (fr)	2004-06-01	Solutions de mitoxantrone stables
JP3720262B2 (ja)	2005-11-24	安定化したカルベジロール注射溶液
JP3744857B2 (ja)	2006-02-15	アルファ−２，４−ジスルホフェニル−Ｎ−ｔｅｒｔ−ブチルニトロンの新規な処方物
Stark et al.	1980	Dissolution of Cystine Calculi by Pelviocaliceal Irrigation with B-Penicillamine
RU2000129666A (ru)	2002-10-10	Стабильные растворы митоксантрона
AU2001260935A1 (en)	2002-02-21	Novel formulations of alpha-2,4-disulfophenyl-N-tert-butylnitrone
CA2496121A1 (fr)	2004-02-26	Formulations stables d'acide hyaluronique pour le traitement therapeutique des arthropathies
NL7906835A (nl)	1980-03-18	Etomidaat-bevattende infusievloeistof, alsmede werkwijze voor het intraveneus toedienen en bereiden daarvan.
KR0156929B1 (ko)	1998-11-16	안정화된수용성펜타미딘염수용액
PE20001597A1 (es)	2001-01-20	Solucion acuosa estable de em 12 (3-(1-oxo-1,3-dihidro-isoindol-2-il)-piperidin-2,6-diona), y procedimiento de preparacion de dicha solucion
US6818662B2 (en)	2004-11-16	Pharmaceutical composition
FR2535205A1 (fr)	1984-05-04	Solution pour injection a base de substances antirhumatismales et d'une cobalamine et procede pour sa preparation
JPS62126130A (ja)	1987-06-08	動物用医薬組成物
JPS62265220A (ja)	1987-11-18	１，４−ジヒドロキシ−５，８−ビス〔２−（２−ヒドロキシエチルアミノ）−エチルアミノ〕アントラキノン二塩酸塩の安定な注射用医薬配合物